Gonococcal antimicrobial susceptibility surveillance in Europe 2011
This report presents the results from the 2011 gonococcal antimicrobial susceptibility surveillance programme (Euro-GASP) and a summary of the second distribution from the 2011 external quality assurance (EQA) scheme. Twenty one EU/EEA Member States participated in the Euro-GASP programme and nineteen in the EQA scheme.
Effective control of gonorrhoea, the second most commonly reported sexually transmitted infection in Europe, relies on successful antimicrobial treatment. As data from the ECDC report Gonococcal antimicrobial susceptibility surveillance in Europe 2011 illustrate, gonococci have become more resistant to common agents for treatment and show reduced susceptibility to newer antibiotics.
The results show that decreased susceptibility to the previously recommended drug for treatment of gonorrhoea, cefixime, was 7.6% in 2011, a small decline as compared to the 8.7% in 2010. Seventeen countries detected isolates with reduced susceptibility to cefixime including four countries which reported these isolates for the first time. In addition, ten isolates (from two countries) with decreased susceptibility to the currently recommended drug for treatment, ceftriaxone, were detected in Euro-GASP for the first time. As control of gonorrhoea relies on effective antimicrobial treatment, the loss of the currently recommended treatment drugs would have a significant impact on public health: with more than 32 000 reported cases in 2010, gonorrhoea is the second most commonly recorded sexually transmitted infection in Europe.In response to this, ECDC launched a regional response plan to control and manage multidrug-resistant gonorrhoea in 2012 in order to minimise the impact of resistant gonorrhoea in Europe
HIV/AIDS surveillance in Europe 2019 - 2018 data
28 Nov 2019 - This report has been published jointly by the European Centre for Disease Prevention and Control (ECDC) and the WHO Regional Office for Europe. The Regional Office developed the overview of the European Region as a whole and validated the figures of the non-member countries of the European Union (EU)/European Economic Area (EEA) and ECDC developed the overview of the EU/EEA countries and validated the EU/EEA figures.
External quality assessment of laboratory performance – European Antimicrobial Resistance Surveillance Network (EARS-Net), 2018
22 Nov 2019 - This report provides an analysis of the external quality assessment (EQA) performance with antimicrobial susceptibility testing (AST) of laboratories participating in the European Antimicrobial Resistance Surveillance Network in 2018. A total of 860 laboratories (1 – 114 per country) from 30 EU/EEA countries participated in the EQA exercise. Six bacterial strains were used: Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Staphylococcus aureus, Enterococcus faecium and Streptococcus pneumoniae.
Surveillance of antimicrobial resistance in Europe 2018
18 Nov 2019 - The results presented in this report are based on antimicrobial resistance (AMR) data from invasive isolates reported to the European Antimicrobial Resistance Surveillance Network (EARS-Net) by 30 European Union (EU) and European Economic Area (EEA) countries in 2019 (data referring to 2018), and on trend analyses of data reported by the participating countries for the period 2015 to 2018.